Literature DB >> 15955522

Trypanosoma cruzi: the effects of dehydroepiandrosterone (DHEA) treatment during experimental infection.

Carla Domingues dos Santos1, Míriam Paula Alonso Toldo, José Clóvis do Prado Júnior.   

Abstract

The aim of this study was to evaluate the efficacy of the immunomodulator dehydroepiandrosterone (DHEA) in the treatment of Trypanosoma cruzi infection and the possible biochemistry alterations in male and female Wistar rats. DHEA also known as the steroid of multiple actions has attracted distinct medical areas. Prior studies show that DHEA enhances immune responses against a wide range of viral, bacterial and parasitic pathogens. Furthermore, administration of DHEA seems to protect animals against obesity and diabetes. Male animals subcutaneous treated with 40 mg/kg body weight/day of DHEA displayed a significant reduction in blood parasites during parasitaemia peak, when compared to untreated animals (P<0.001). For female group parasitaemia was also reduced although values are not statistically significant (P>0.05). Sexual dimorphism was also observed, since females displayed lesser parasitaemia levels compared to males group treated (P>0.05) and untreated (P<0.001). Enhanced leucocytes number was observed in control females when compared to control males (P<0.05). DHEA treatment did not triggered any significant alterations in leucocytes levels (P>0.05). DHEA administration induced an enhanced number of macrophages in infected male (P<0.01). DHEA administration causes a decrease in glucose (P<0.001). Cholesterol and tryglicerides levels did not display results statistically significant (P>0.05) during the treatment. These results suggest that DHEA treatment enhances the immune response as evidenced here by reduced levels of parasites. Up-regulation of the immune system by exogenous DHEA may be useful in the treatment of American tripanosomiasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15955522     DOI: 10.1016/j.actatropica.2005.05.005

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  7 in total

Review 1.  Boosting the Discovery of Small Molecule Inhibitors of Glucose-6-Phosphate Dehydrogenase for the Treatment of Cancer, Infectious Diseases, and Inflammation.

Authors:  Ana Koperniku; Adriana A Garcia; Daria Mochly-Rosen
Journal:  J Med Chem       Date:  2022-03-03       Impact factor: 8.039

2.  The effect of ageing on human lymphocyte subsets: comparison of males and females.

Authors:  Jun Yan; Judith M Greer; Renee Hull; John D O'Sullivan; Robert D Henderson; Stephen J Read; Pamela A McCombe
Journal:  Immun Ageing       Date:  2010-03-16       Impact factor: 6.400

3.  Role of serum dehydroepiandrosterone sulfate level on the clearance of chronic hepatitis B virus infection.

Authors:  Jia-Feng Wu; Wen-Yu Tsai; Yi-Ching Tung; Huey-Ling Chen; Yen-Hsuan Ni; Hong-Yuan Hsu; Mei-Hwei Chang
Journal:  J Gastroenterol       Date:  2013-06-01       Impact factor: 7.527

4.  Glucose-6-phosphate dehydrogenase of trypanosomatids: characterization, target validation, and drug discovery.

Authors:  Shreedhara Gupta; Mariana Igoillo-Esteve; Paul A M Michels; Artur T Cordeiro
Journal:  Mol Biol Int       Date:  2011-04-04

5.  Dehydroepiandrosterone exacerbates nigericin-induced abnormal autophagy and pyroptosis via GPER activation in LPS-primed macrophages.

Authors:  Ji Cao; Longlong Li; Yao Yao; Yuxiao Xing; Haitian Ma
Journal:  Cell Death Dis       Date:  2022-04-19       Impact factor: 9.685

6.  Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole.

Authors:  Bertrand Nyuykonge; Wilson Lim; Lukas van Amelsvoort; Alexandro Bonifaz; Ahmed Fahal; Hamid Badali; Mahdi Abastabar; Annelies Verbon; Wendy van de Sande
Journal:  Mycoses       Date:  2022-05-06       Impact factor: 4.931

7.  A new parasiticidal compound in T. solium cysticercosis.

Authors:  Romel Hernández-Bello; Galileo Escobedo; Julio Cesar Carrero; Claudia Cervantes-Rebolledo; Charles Dowding; James Frincke; Chris Reading; Jorge Morales-Montor
Journal:  Biomed Res Int       Date:  2012-12-20       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.